Biomarkers in the diagnosis of anaphylaxis: Making nature disclose her mysteries

Clinical and Experimental Allergy

Volumn 39, Issue 1, 2009, Pages 5-7

  Levy, J H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARGIPRESSIN; BIOLOGICAL MARKER; IMMUNOGLOBULIN E; VANCOMYCIN;

ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIGEN ANTIBODY REACTION; EDITORIAL; HEALTH CARE COST; HUMAN; IMMUNOPATHOGENESIS; MAST CELL DEGRANULATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ADULT; ANAPHYLAXIS; BIOLOGICAL MARKERS; CHILD; CYSTEINE; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENE E4; LEUKOTRIENES; MAST CELLS; PROSTAGLANDIN D2;

EID: 58149218413     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03136.x     Document Type: Editorial

References (18)

1. Sampson HA, Munoz-Furlong A, Bock SA et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005 115 : 584 91.
2. Gruchalla RS, Pirmohamed M. Clinical practice. Antibiotic allergy. N Engl J Med 2006 354 : 601 9.
3. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000 30 : 1144 50.
4. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007 120 : 506 15.
5. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001 344 : 30 7.
6. Bani D, Nistri S, Mannaioni PF, Masini E. Cardiac anaphylaxis: pathophysiology and therapeutic perspectives. Curr Allergy Asthma Rep 2006 6 : 14 9.
7. Cohen SG, Zelaya-Quesada M. Portier, Richet, and the discovery of anaphylaxis: a centennial. J Allergy Clin Immunol 2002 110 : 331 6.
8. Veien M, Szlam F, Holden JT, Yamaguchi K, Denson DD, Levy JH. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000 92 : 1074 81.
9. Vadas P, Gold M, Perelman B et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008 358 : 28 35.
10. Ono E, Taniguchi M, Mita H et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2009 39 : 72 80.
11. Smith PL, Kagey-Sobotka A, Bleecker ER et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980 66 : 1072 80.
12. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004 4 : 285 90.
13. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001 345 : 588 95.
14. Cauwels A, Janssen B, Buys E, Sips P, Brouckaert P. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 2006 116 : 2244 51.
15. Tsuda A, Tanaka KA, Huraux C et al. The in vitro reversal of histamine-induced vasodilation in the human internal mammary artery. Anesth Analg 2001 93 : 1453 9.
16. Krismer AC, Dunser MW, Lindner KH et al. Vasopressin during cardiopulmonary resuscitation and different shock states: a review of the literature. Am J Cardiovasc Drugs 2006 6 : 51 68.
17. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 2004 134 : 260 1.
18. Evora PR. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock. J Thorac Cardiovasc Surg 2000 119 : 632 4.